ArticleIDCases2025
Perforated colon cancer complicated by necrotizing soft tissue infection: A case report and literature review.
Article in IDCases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Necrotizing soft tissue infections (NSTIs) are rare but life-threatening complications of colorectal cancer, often overlooked during patient diagnosis and treatment. NSTIs progress rapidly, leading to significant tissue damage and elevated mortality rates. This report presents the case of a 71-year-old male who presented with abdominal pain and distention, later diagnosed with perforated colon cancer and NSTI of the left abdominal wall. Following admission, the patient developed septic shock and acute kidney injury. Emergency surgery was performed, including radical resection of the colon cancer, proximal colostomy, and extensive debridement of necrotic tissue. Postoperatively, Continuous Renal Replacement Therapy (CRRT) was used alongside standard treatments, contributing to a relatively rapid recovery. At the 30-month follow-up, no evidence of tumor recurrence was observed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.